Logo image of LUCY

INNOVATIVE EYEWEAR INC (LUCY) Stock Fundamental Analysis

NASDAQ:LUCY - Nasdaq - US45791D2080 - Common Stock - Currency: USD

2.12  -0.04 (-1.85%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LUCY. LUCY was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While LUCY has a great health rating, there are worries on its profitability. LUCY is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LUCY had negative earnings in the past year.
In the past year LUCY has reported a negative cash flow from operations.
LUCY had negative earnings in each of the past 5 years.
In the past 5 years LUCY always reported negative operating cash flow.
LUCY Yearly Net Income VS EBIT VS OCF VS FCFLUCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

The Return On Assets of LUCY (-95.37%) is worse than 79.14% of its industry peers.
The Return On Equity of LUCY (-101.07%) is worse than 62.03% of its industry peers.
Industry RankSector Rank
ROA -95.37%
ROE -101.07%
ROIC N/A
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCY Yearly ROA, ROE, ROICLUCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

LUCY has a Gross Margin of 25.11%. This is in the lower half of the industry: LUCY underperforms 77.54% of its industry peers.
In the last couple of years the Gross Margin of LUCY has declined.
LUCY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 25.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
LUCY Yearly Profit, Operating, Gross MarginsLUCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUCY has more shares outstanding
The number of shares outstanding for LUCY has been reduced compared to 5 years ago.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LUCY Yearly Shares OutstandingLUCY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
LUCY Yearly Total Debt VS Total AssetsLUCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

An Altman-Z score of 2.29 indicates that LUCY is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of LUCY (2.29) is better than 61.50% of its industry peers.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.29
ROIC/WACCN/A
WACC9.07%
LUCY Yearly LT Debt VS Equity VS FCFLUCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 16.39 indicates that LUCY has no problem at all paying its short term obligations.
LUCY has a better Current ratio (16.39) than 97.33% of its industry peers.
A Quick Ratio of 13.87 indicates that LUCY has no problem at all paying its short term obligations.
The Quick ratio of LUCY (13.87) is better than 96.26% of its industry peers.
Industry RankSector Rank
Current Ratio 16.39
Quick Ratio 13.87
LUCY Yearly Current Assets VS Current LiabilitesLUCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

8

3. Growth

3.1 Past

LUCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.12%, which is quite impressive.
The Revenue has grown by 22.74% in the past year. This is a very strong growth!
Measured over the past years, LUCY shows a very strong growth in Revenue. The Revenue has been growing by 33.36% on average per year.
EPS 1Y (TTM)52.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)22.74%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%18.8%

3.2 Future

LUCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.10% yearly.
Based on estimates for the next years, LUCY will show a very strong growth in Revenue. The Revenue will grow by 224.44% on average per year.
EPS Next Y66.67%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year294.74%
Revenue Next 2Y224.44%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LUCY Yearly Revenue VS EstimatesLUCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
LUCY Yearly EPS VS EstimatesLUCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUCY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCY Price Earnings VS Forward Price EarningsLUCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCY Per share dataLUCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

LUCY's earnings are expected to grow with 41.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUCY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVATIVE EYEWEAR INC

NASDAQ:LUCY (7/16/2025, 12:40:03 PM)

2.12

-0.04 (-1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners0.57%
Inst Owner Change0%
Ins Owners32.34%
Ins Owner Change0%
Market Cap6.55M
Analysts82.86
Price Target7.14 (236.79%)
Short Float %11.86%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-43.84%
Min Revenue beat(2)-55.39%
Max Revenue beat(2)-32.28%
Revenue beat(4)0
Avg Revenue beat(4)-56.61%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-32.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.59%
EPS NY rev (1m)-8.33%
EPS NY rev (3m)35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-27.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.84
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)-4.45
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-2.53
FCFYN/A
OCF(TTM)-2.45
OCFYN/A
SpS0.55
BVpS2.43
TBVpS2.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.37%
ROE -101.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 25.11%
FCFM N/A
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.93%
Cap/Sales 14.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.39
Quick Ratio 13.87
Altman-Z 2.29
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)402.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.82%
Cap/Sales(5y)37.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y66.67%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.74%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%18.8%
Revenue Next Year294.74%
Revenue Next 2Y224.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.64%
OCF growth 3YN/A
OCF growth 5YN/A